您现在将离开 Xalutestudy.com，并进入一个可信赖的合作伙伴网站。
Xaluritamig 是一种正在研制的试验性新型 T 细胞接合剂免疫疗法，可用于治疗晚期前列腺癌。通过在免疫 T 细胞和 STEAP1（一种在前列腺癌细胞中独特地过度表达的蛋白质）之间建立免疫突触，Xaluritamig 旨在激活免疫系统，对抗前列腺癌细胞。1-3
1 Kelly WK, Danila DC, Lin CC, et al. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024;14(1):76-89. doi: 10.1158/2159-8290
2 Nolan-Stevaux O, Li C, et al. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer. Cancer Discov.2024 Jan 12;14(1):90-103. doi: 10.1158/2159-8290
3 Xu M, Evans L, Bizzaro CL, et al. STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer. Cancers (Basel).2022;14(16):4034. doi: 10.3390/cancers14164034
